Monitor the outcome of the annual meeting votes, particularly the say-on-pay proposal, for any signal of shareholder discontent. No immediate trading catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Oct 2 $218.89entry
- T+1 · 6w ago +1.81%α +1.14% · $222.86
- T+5 · 6w ago +5.10%α +3.94% · $230.05
- T+20 · 18d ago +5.05%α +6.86% · $229.94
- T+31 · todayOpen
- T+60 · in 6w Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ResMed filed a DEFA14A (additional definitive proxy soliciting material) on October 1, 2026, providing a voting instruction card for the 2026 Annual Meeting scheduled for November 18, 2026 (US time) / November 19, 2026 (Australian time). The filing is a routine solicitation by management, recommending votes FOR all 10 director nominees, FOR ratification of PricewaterhouseCoopers as auditor, and FOR advisory approval of executive compensation. No dissident or activist campaign is evident from this filing.
Key Financial Metrics
Key Facts
- Annual Meeting: November 18, 2026 (US Pacific) / November 19, 2026 (Australian Eastern Time)
- Management recommends voting FOR all 10 director nominees
- Management recommends voting FOR ratification of PricewaterhouseCoopers as auditor for FY ending June 30, 2027
- Management recommends voting FOR advisory approval of named executive officer compensation
- Meeting will be held virtually via www.virtualshareholdermeeting.com/RMD2026
Financial Impact
No financial impact, routine proxy solicitation with no material financial terms disclosed.
Risk Factors
- Low risk, routine proxy solicitation with no contested items or activist involvement.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0000943819-26-000082 |
| Document: 0000943819-26-000082-index.html | 0000943819-26-000082 |
| Document: 0000943819-26-000082.txt | 0000943819-26-000082 |
Track record
19 reports on RMD
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +28.97% at T+60 after the Jun 1, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $234.11 Now $238.19 +1.74% settles Dec 9
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $229.94 Now $238.19 +3.59% settles Nov 30
- Oct 16, 20264w ago Institutional Cluster Bearish 4/10 Entry $238.88 to $238.19 Now $238.19 +0.29% ▲ +0.29% −3.17% vs SPY
- Oct 7, 20265w ago 144 Neutral 3/10 Entry $226.73 to $240.51 Now $238.19 +5.05% ▲ +6.08% +11.37% vs SPY
- Oct 1, 20266w ago DEFA14A Neutral 2/10 Viewing Entry $218.89 to $229.94 Now $238.19 +8.82% ▲ +5.05% +6.86% vs SPY
- Oct 1, 20266w ago DEF 14A Neutral 4/10 Entry $218.89 to $252.83 Now $238.19 +8.82% ▲ +15.51% +17.31% vs SPY
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $218.89 Now $238.19 +8.82% No price data
- Sep 10, 20269w ago Insider Cluster Neutral 4/10 Entry $219.58 to $226.73 Now $238.19 +8.48% ▲ +3.26% +1.13% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 2/10 Entry $224.84 to $219.95 Now $238.19 +5.94% ▼ −2.17% −1.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers